Alzheon, a developer of Alzheimer's drugs, has closed a $100 million Series E financing round to fund the completion of a pivotal Phase III trial and regulatory filings for its lead candidate. Biogen's Alzheimer's drug, Leqembi, is expected to perform well in the market according to a company executive at the Goldman Sachs Global Healthcare Conference. Alzheon aims to disrupt the Alzheimer's drug field with the funding. The FDA is considering a new Alzheimer's medication, prompting experts to discuss the rollout of similar drugs.
Alzheon lands $100m to advance oral Alzheimer’s drug towards commercialization Funding to complete ongoing Phase 3 trial and commercial launch of first oral disease-modifying therapy for Alzheimer’s. #longevity #investment #biotech #Alzheimers https://t.co/aH4hFn3FvQ https://t.co/1owhXleI6E
Leqembi and Alzheimer’s: What to Know About the New Drug, Treatment and Benefits - “As the F.D.A. considers a new Alzheimer’s medication, we asked experts how the rollout of a similar drug has gone.” https://t.co/PPTZWtZ10U
12June: How does @Alzheon plan to use the proceeds of its just-closed $100 million Series E financing? Read what CEO @MartinTolar MD, PhD told me about how his company aims to disrupt the Alzheimer's disease disease drug field in my latest for @GENbio: https://t.co/TVxd1HNewy
Biogen's Alzheimer's drug, Leqembi, will do well in the market whether a competitor comes or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday. https://t.co/xGVsAvY0hc https://t.co/xGVsAvY0hc
Biogen's Alzheimer's drug, Leqembi, will do well in the market, whether a competitor will come or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday. https://t.co/DlgbkgQroR https://t.co/DlgbkgQroR
Alzheimer's Drug Developer Alzheon Closes $100M Series E Financing Alzheon says it expects to fund the completion of a pivotal Phase III trial and regulatory filings later this year for its lead candidate. Learn more: https://t.co/4Bmh51C4nS https://t.co/bhuz1Vjoz9